title: Increased relapse rates in early stage hodgkin lymphoma (HL) patients without radiotherapy: the German Society of Radiooncology (DEGRO) advises to treat all early stage HL patients with radiotherapy.
authors.forename: D
authors.initials: D
authors.lastname: Körholz
authors.forename: C
authors.initials: C
authors.lastname: Mauz-Körholz
authors.forename: D
authors.initials: D
authors.lastname: Vordermark
authors.forename: R
authors.initials: R
authors.lastname: Kluge
authors.forename: K
authors.initials: K
authors.lastname: Dieckmann
mesh_terms: D000293:Adolescent; D002648:Child; D006801:Humans; D055815:Young Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000517:prevention & control; D009367:Neoplasm Staging; D009381:Neoplasms, Radiation-Induced / Q000209:etiology / Q000517:prevention & control; D016609:Neoplasms, Second Primary / Q000209:etiology / Q000517:prevention & control; D049268:Positron-Emission Tomography; D011832:Radiation Injuries / Q000209:etiology; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D003606:Dacarbazine; D004317:Doxorubicin; D019788:Fluorodeoxyglucose F18; D014747:Vinblastine